Trinity Biotech (TRIB) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Trinity Biotech has reported promising preliminary revenue figures for the second quarter of 2024, expecting to hit $15.5-$16.0 million, which marks a solid year-over-year growth. The company has also secured a distribution agreement with MedScience in the UK to enhance the reach of its clinical chemistry, infectious disease, and autoimmune products. They remain on track to achieve their financial goal of an annualized run-rate EBITDASO of $20 million on revenues of about $75 million by Q2 2025.
For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.